Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation

Abstract

The aim of this study was to estimate the prevalence of total antibodies to hepatitis A virus (anti-HAV-T) in the group of HIV-positive adults in Lodz region of Poland, and to evaluate the response and long-term immunity after vaccination against hepatitis A virus. In the group of 234 HIV-infected patients, 72 persons (30.8%) were anti-HAV-T positive (>20 IU/L). In multivariate analysis, two independent factors associated with the presence of anti-HAV-T were identified: the age of patients (OR = 1.07) and the presence of antibodies to hepatitis C virus (OR = 2.87). Vaccination was completed in 83 patients. Good response (anti-HAV-T >20 IU/L one month after the booster dose) was obtained in 79.5% of patients. In patients with CD4 >200 cells/µL in multivariate analysis only presence of antibodies to hepatitis C virus was a prognostic factor for the response to vaccination (OR = 0.13). Among responders available for the follow-up, 82% (50 out of 61) had detectable anti-HAV-T at 1 year and 75.5% (37 out of 49) at 5 years. Our results demonstrate that most of the studied HIV-positive patients were susceptible to hepatitis A virus infection. Most HIV-infected adults with high CD4 counts had a durable response even up to 5 years after vaccination. Patients with a HIV/hepatitis C virus coinfection displayed a worse response to vaccination.

Keywords

HIV AIDS hepatitis A virus vaccination prognostic factors response hepatitis C

Get full access to this article

View all access options for this article.

References

Fonquernie

Meynard

Charrois

. Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 32: 297–299.

Vento

Garofano

Renzini

. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286–290.

Jabłonowska

Małolepsza

. Profile of patients with newly diagnosed HIV in the Łódź region in Poland from 1996 to 2005. Arch Med Sci 2009; 5: 577–582.

Ida

Tachikawa

Nakajima

. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 2002; 34: 379–385.

Costa-Mattioli

Allavena

Poirier

. Prolonged hepatitis A infection in an HIV-1 seropositive patient. J Med Virol 2002; 68: 7–11.

Magdzik

. Epidemiologic aspects of viral hepatitis A and vaccination. Przegl Epidemiol 2004; 58: 51–59.

Magdzik

. Hepatitis A in Poland in 2003. Przegl Epidemiol 2005; 59: 289–295.

Ślusarczyk

. Vaccination against hepatitis viruses in Poland. Vaccine 2001; 19: 2384–2348.

Reimer

Lorenzen

Baetz

. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol 2007; 22: 80–85.

10.

Villano

Nelson

Vlahov

. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin Infect Dis 1997; 25: 726–728.

11.

Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases the pink book, http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepa.pdf (2012, accessed 11 November 2013).

12.

Tedaldi

Baker

Moorman

. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38: 1478–1484.

13.

Neilsen

Bodsworth

Watts

. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997; 176: 1064–1067.

14.

Overton

Nurutdinova

Sungkanuparph

. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007; 14: 189–193.

15.

Santagostino

Gringeri

Rocino

. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost 1994; 72: 508–510.

16.

Wallace

Brandt

Earhart

. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39: 1207–1213.

17.

Weissman

Feucht

Moore

. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat 2006; 13: 81–86.

18.

Clemens

Safary

Hepburn

. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171: S44–S49.

19.

VAQTA hepatitis A vaccine, inactivated [prescribing information] Whitehouse Station, New Jersey: Merck and Company, http://merck.com/product/usa/pi_circulars/v/vaqta/vaqta_pi.pdf. (2010, accessed 11 November 2013).

20.

Crum-Cianflone

Wilkins

Lee

. Infectious Disease Clinical Research Program HIV Working Group. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011; 203: 1815–1823.

21.

Kourkounti

Mavrianou

Paparizos

. Immune response to hepatitis A vaccination in HIV-infected men in Greece. Int J STD AIDS 2012; 23: 464–467.

22.

Weinberg A, Gona P, Nachman SA, et al. Pediatric AIDS Clinical Trials Group 1008 Team. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006; 193: 302–311.

23.

From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269: 729–730.

24.

Launay

Grabar

Gordien

. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008; 49: 272–275.

25.

Tseng

Chang

Liu

. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatology 2013; 57: 1734–1741.